VITURA

ASX:VIT

ASX ANNOUNCEMENT

INVESTOR WEBINAR

1 NOVEMBER 2023

Melbourne, Australia - Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to confirm that an investor webinar to discuss the Company's acquisition of Doctors on Demand Pty. Ltd. and what it means for Vitura Health going forward will be held today at 10.00 am (Melbourne time).

The attached presentation will be used in the webinar.

Link: https://loghic.eventsair.com/vit-investor-update/register/Site/Register

** ENDS **

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra Victoria 3141, Australia VITURA.COM.AU









About Vitura Health Limited (ASX:VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

• www.burleighheadscannabis.com

Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 260+ product SKUs within Australia from 39 international and domestic medicinal cannabis brands.

• www.canview.com.au

CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The CanView system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up CanView, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, CanView provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the CanView platform, without the need to input the patient's details. Prescriptions are then sent directly to the CanView patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the 3,600+ Australian pharmacies with accounts on CanView for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

• <u>www.doctorsondemand.com.au</u>

The Company owns Doctors on Demand Pty Ltd, a nationwide $24/7 \times 365$ telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.

• <u>www.cortexa.com.au</u>

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

• <u>www.cdaclinics.com.au</u>

The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.



• www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

Authorised by

Rodney Cocks, Chief Executive Officer and Executive Director

Contact

Vitura Health Limited

Rodney Cocks Chief Executive Officer and Executive Director 1300 799 491 info@vitura.com.au

Media enquiries

Tim Fogarty
The Civic Partnership
+61 400 179 075

tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.





DOCTORS ON DEMAND ACQUISITION Investor Webinar

01 November 2023

Innovating the delivery of healthcare

Today's Focus - The Doctors on Demand Acquisition

Members of the Vitura Executive will walk you through the transaction to acquire 100% of Doctors on Demand, including the model, rationale, structure and integration – and take your questions on the deal



Executive Summary - DoD, a value accretive acquisition

We are excited to have, on 26OCT23, closed the transaction to acquire 100% of Doctors on Demand a nationwide 24/7x365 telehealth platform business with a current consults annual run rate of ~300k consults

- Doctors on Demand (DoD) was established in 2015 and is a leading 24/7 x 365 telehealth platform that provides B2C and B2B consults to hundreds of thousands of patients nationwide
- Record revenues and consults numbers are currently being achieved by DoD in both the B2C and B2B businesses with daily, weekly, monthly and quarterly records being hit at acquisition
- o **Acquisition based on a sound strategic rationale** to solidify VIT as a true digital health business, acquire significant numbers of prescribers and patients, and move into new product and service verticals, while future proofing the company for sustainable growth and profitability
- o Consideration stack of \$25m comprising of cash, debt, equity and vendor finance
- o **Telehealth as a strong thematic** where the widespread adoption of telehealth is being partly driven by costof-living pressures, availability of doctors and pressure on clinics from some state governments enforcing the collection of payroll tax for contracted doctors, all dynamics that are likely to continue into the future
- Supports our Vision26 Strategy which is focussed on strategic objectives to drive growth
- o Integration is well underway and expected to be largely complete within 100 days






DoD is a leading nationwide 24/7x365 telehealth business

The building blocks of the Doctors of Demand business have evolved over the last 8+ years into a marketing leading telehealth platform consulting to hundreds of thousands of patients

- DoD was established in 2015 by John Martin and John Neilson to address the issue of their pharmacy staff in Mt Isa, Queensland, being unable to readily access healthcare services and grew from there
- DoD was the pioneer in telehealth in Australia, with its inception and development pre dating the COVID-19 adoption of telehealth
- The COVID-19 pandemic was a huge catalyst for wide-spread adoption of telehealth with practitioners and patients
- This trend has been supported by companies such as Sigma,
 Wesfarmers and large private health insurers buying or taking large stakes in telehealth businesses like DoD
- The key point of differentiation with DoD is that the business is not only consults B2C patients, with a significant amount of their revenue being derived from B2B customers, including large Australian insurers and corporates



The DoD model - telehealth pricing and consult offerings

DoD offers a full-service consultation telehealth business model on its sophisticated platform, however, is not currently involved in medications / products for its patients



DoD consultation pricing (all out of pocket, no Medicare benefit)

- o Business hours consults (8am-6pm) \$60
- After hours consults (6pm-8am), weekends, public holidays \$90
 Booking fee of \$2.95 for each consult
 - o Medication not included, paid for when dispened at pharmacy

- o Consults are available 24 / 7 x 365
- All interactions are via the **DoD website or App** (available on the Apple and Google App Store), including payments, video
 consultation and prescriptions
- Large, and growing B2C and B2B businesses
- The services DoD offer are akin to a physical bricks and mortar clinic, offering the full range of consultations, medical certificates, specialist referrals, pathology referrals etc.
- Additionally, they also offer Smoking Cessation and Medicated Weight Loss consultations and programs
- No asynchronous based consults that were prevalent during the COVID-19 pandemic
- Well established and recognised in market brand in both B2C and B2B markets

DoD is achieving record revenues and consult numbers

DoD are experiencing record QoQ and MoM growth of both revenue and consults, proving a significant platform for growth and resourcing of strategic projects in the business

1. Record Financial Achievements at Acquisition

- o As at completion of the transaction, Vitura expects DoD to generate positive net cash flows
- **Record quarterly revenue** for Q1 FY2024 of \$4.32m (unaudited)
- o Record QoQ revenue growth of 29% growth in revenue Q1 FY2024 as compared to Q1 FY2023
- Record monthly revenue achieved in September 2023 of \$1.52m (unaudited)
- o **Record B2B revenue growth** of 151% growth in volume of B2B business customer rev<mark>enue in Q1 FY2024 compared to Q1 FY2023</mark>

2. Record Operational Achievements at Acquisition

- o **Doctors** that currently treat patients on the DoD platform number 120+
- o Record annual medical consult run rate of consults as at September 2023 of 280,000+ consults ARR
- Record quarterly medical consults for Q1 FY2024 of 65,000+ medical consults
- o Record monthly medical consults for September 2023 of 23,200 medical consults
- **Record daily medical patient consults** in a single 24-hour period during September 2023 of 1,040 which equates to an average of 43 patient consults per hour

Sound strategic rationale for the DoD transaction

The transaction is expected to deliver VIT a range of immediate financial and non-financial benefits

- The DoD transaction is built on a sound strategic rationale to solidify Vitura as a true digital health player, acquire significant numbers of prescribers and patients, move into new product and service verticals, diversify our revenue sources - in order to contribute to our sustainable growth and profitability over the long term
- This rationale is supported by a full human capital cohort of leadership from DoD, an in-market tech stack, significant brand equity in the minds of patients and businesses, and existing deep relationships with some of Australia's largest health insurers and corporates
- o While DoD is achieving commercial success now, we believe that with Vitura's capital, leadership and proven distribution model we can bring to market **new verticals whilst growing existing verticals** in a very short time
- The DoD commercial outlook is strong, we are acquiring the business at a time when it is achieving record revenues and consults on a daily, weekly, monthly basis paving a clear path to growth
- o In a single transaction we significantly **expand of our total addressable market (TAM),** moving from a TAM in the hundreds of thousands of potential patients to millions with DoD
- o DoD has the right strategy that can be executed together with the Vitura team and its resources. We believe that DoD have the right strategy, however will benefit from capital and Executive leadership, support and inputs. The B2C segment continues to thrive in the market and will react positively to additional advertising spend. While the B2B segment of the business shows exciting growth prospects through additional insurer and corporate partnerships
- The transaction also buttresses Vitura's commitment to clinical governance with an established Clinical Advisory Group and a Chief Medical Officer currently being recruited to support all of Vitura's clinical operations

Deal structure - \$25m in cash, equity, debt, vendor finance

The consideration stack comprises four tranches of different funding sources and time frames

1. Cash from VIT Balance Sheet Paid at closing on 26OCT23

\$6.25m

3. Debt facility from the ANZ Bank

BBSW + 2.58% Repayable over 5 years Drawn down at closing on 26OCT23 \$6.25m

2. VIT shares at a 7 trading day VWAP to the announcement date (190CT23)

\$6.25m of VIT shares (All of these shares were issued to Regal Funds entities) at \$0.3596 per share for a total of 17,380,423 VIT shares

4. Vendor finance **Deferred payment to vendors** in cash on closing date + 12 months

0% interest \$6.25m

Payable in cash in 12 months (26OCT24)

How the transaction supports Vision26


The acquisition of Doctors on Demand supports the strategic objectives of Vision26, Vitura's strategy that extends to the end of Financial Year 2026



Comparable transaction - Wesfarmers/API + InstantScripts

The most significant transaction in the telehealth space in Australia was the purchase of InstantScripts by Wesfarmers business API for \$135m in June 2023

- Wesfarmer's wholly owned pharmaceutical distribution business purchased 100% of InstantScripts in June 2023
- o Summary of AFR reporting:
 - o Purchase price \$135m
 - o Revenue at completion ~\$50m
 - 250,000 patients
 - Links to 40% of pharmacies nationwide
 - Access to 300 prescription medicines
- Based on these reported numbers that equates to an implied revenue multiple of 2.7x for the acquisition of InstantScripts
- o InstantScripts were previously undertaking asynchronous consults, which were the subject of regulatory change by the Federal Health Department prohibiting that consult modality
- o AFR Article reference (from 12JUN23) on right



The five-year-old startup lets patients obtain express medical scripts in minutes online for more than 300 medicines. It has landed on Wesfarmers' radar, as the \$54 billion listed group builds out its health division, led by Hatfield, and has been looking for businesses that would disrupt the status quo and bring efficiencies to the heath system.

Integration of DoD into VIT - the first 100 days

Integration of the DoD business into VIT commence pre closing and will be largely complete within 100 days

Strategy – Vision26 iteration based on DoD acquisition

Operations

Human Capital

Finance

IT

Marketing

Clinical Governance, Legal & Regulatory

Communications – Internal & External

Systems, Processes & Policies

VIT 100 Day Plan for Integration of Doctors on Demand

Human Capital Integration - Full leadership team

We will retain, and integrate, the DoD leadership into VIT to drive the continued growth of the business while not interrupting the momentum that has been achieved – and foster as positive culture



- o Kirsty Garrett Has been appointed as Vitura Health Chief Operating Officer
- o Formerly DoD Chief Executive Officer
- o Will be responsible for DoD, CDA/Cannadoc, Technology, People & Culture
- o Strong corporate leadership, med tech, IT and software background

All the Doctors on Demand Leadership Team are joining Vitura



Amanda Yeates Clinical
Governance &
Programs
Manager



Oliver Sherlock Corporate
Partnerships
Manager



Mike Moran -Software Development Manager



Cassandra
Matcham DoD Head of
Marketing &
Digital



Carla Swan DoD Customer
Success
Manager

Summary - DoD, a value accretive acquisition

We are excited to have, on 26OCT23, closed the transaction to acquire 100% of Doctors on Demand a nationwide 24/7x365 telehealth platform business with a current consults annual run rate of ~300k consults

- **Doctors on Demand (DoD)** was established in 2015 and is a leading 24/7 x 365 telehealth platform that provides B2C and B2B consults to hundreds of thousands of patients nationwide
- Record revenues and consults numbers are currently being achieved by DoD in both the B2C and B2B businesses with daily, weekly, monthly and quarterly records being hit at acquisition
- Acquisition based on a sound strategic rationale to solidify VIT as a true digital health business, acquire significant numbers of prescribers and patients, and move into new product and service verticals, while future proofing the company for sustainable growth and profitability
- o Consideration stack of \$25m comprising of cash, debt, equity and vendor finance
- o **Telehealth as a strong thematic** where the widespread adoption of telehealth is being partly driven by costof-living pressures, availability of doctors and pressure on clinics from some state governments enforcing the collection of payroll tax for contracted doctors, all dynamics that are likely to continue into the future
- Supports our Vision26 Strategy which is focussed on strategic objectives to drive growth
- o Integration is well underway and expected to be largely complete within 100 days





13

Your questions - please enter into the system chat box

You will be able to enter your questions into the system chat box which the Executive will answer for you







Doctors on Demand

healthcare video consults

doctorsondemand.com.au



Disclaimer applying to this Presentation

The following disclaimer applies to this presentation (Presentation)

You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation has been prepared by Vitura Health Limited (Vitura or Company).

Not investment advice

The information contained in this Presentation is not investment or financial product advice or any recommendation to acquire Shares. This Presentation does not and will not form any part of any contract for the acquisition of Shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation.

Future performance

This Presentation contains forward looking statements and comments about future events, including Vitura's expectations about the performance of its business. Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions.

You are cautioned not to place undue reliance on any forward-looking statement. While due care and attention has been used in the preparation of forward-looking statements, forward looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends which are based on interpretations of current market conditions. Forward looking statements should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Vitura.

A number of important factors could cause the actual conduct, results, performance or achievement of Vitura to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. Actual results, performance or achievements may vary materially from any forward-looking statements and the assumptions on which statements are based. Vitura disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise.

The forward-looking statements are based on information available to Vitura as at the date of this Presentation. Except as required by law or regulation, Vitura undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Summary information

This Presentation contains summary information about Vitura and its activities which is current only as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Vitura or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth.) (Corporations Act).

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Vitura nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.

Not an offer

This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

